A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
about
Anti-vascular endothelial growth factor therapy in breast cancerBevacizumab in ovarian cancer: A critical review of phase III studiesBevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.Nab-paclitaxel, docetaxel, or solvent-based paclitaxel in metastatic breast cancer: a cost-utility analysis from a Chinese health care perspective.Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis.Cost-utility analyses of drug therapies in breast cancer: a systematic review.Economic evaluation of brentuximab vedotin for persistent Hodgkin lymphoma.Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer.The life, death, and attempted rebirth of bevacizumab in breast cancer.Trends and issues in oncology costs.Bevacizumab: a review of its use in advanced cancer.VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.Recent development of targeted approaches for the treatment of breast cancer.The impending financial healthcare burden and ethical dilemma of systemic therapy in metastatic cancer.Reviewing the quality, health benefit and value for money of chemotherapy and targeted therapy for metastatic breast cancerA cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.Angiogenesis in spontaneous tumors and implications for comparative tumor biology.Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.A novel synergistic effect of iron depletion on antiangiogenic cancer therapy.Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
P2860
Q26999473-76378C6F-1C38-4097-A1A2-450D0C2138B0Q28076188-B7D550B3-5F36-4D7D-A8C0-1048DB2C2B68Q33577818-5F2A0987-BE94-409C-8CD4-A2CC60810829Q35617654-3ABD3B6F-FBAE-400D-83CD-AA5DEA4BAB36Q35723085-48E5ED00-5A12-43E2-82A1-D77DCFB312D0Q36116276-3E20F125-3260-4204-9563-87838F69D7B2Q37672032-DF013536-29BD-4C5D-887D-749A57C1A938Q38046514-B9B1020A-0F2F-4327-B127-07926EF3FEADQ38160648-D48AF01D-6D36-4B78-B8B2-E8D7A11F0399Q38170426-E2CBCA25-B3F6-485D-8537-16C2E36D9F4AQ38260176-7456C69B-91C4-47C6-B004-24355A44C8E5Q38462868-439E317E-8A62-4FDD-B35B-430877633A56Q38802191-F0C333F3-7387-4AA4-9C00-3C10502E3FB0Q38885867-5D0FCDB5-51F3-4E51-8294-2BCDAB697FB9Q39423484-09F877B4-B770-4F30-9B68-D342FBDD94BEQ48357233-448A37BC-F7D3-4B8D-9BDA-AA4C927A2FBCQ51301228-7D252DD8-78AB-4FE8-BFD3-9970977C1633Q51544368-85885178-6454-4A42-900A-04A7A9A96654Q53133559-682700A2-9F93-412F-9D57-3BB16FE425F6Q54196655-6A84C606-2AF1-4310-AB5E-8994B460F9EE
P2860
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@ast
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@en
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@nl
type
label
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@ast
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@en
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@nl
prefLabel
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@ast
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@en
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@nl
P2093
P2860
P1476
A cost-benefit analysis of bev ...... with metastatic breast cancer.
@en
P2093
Alberto J Montero
Gilberto Lopes
Kiran Avancha
Stefan Glück
P2860
P2888
P304
P356
10.1007/S10549-011-1919-Y
P407
P577
2011-12-27T00:00:00Z
P5875
P6179
1045904951